Weeks after laying off 'substantially all' employees, Acasti Pharma insists its approval plans remain on track

Laying off “substantially all” your workforce is normally a sign that a biotech is in a death spiral, but Acasti Pharma’s CEO is insistent that the move has “energized” the company as it gears up for a phase 3 study of its lead asset.